文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

NRAS 突变体能增强黑色素瘤起始过程中的 BRAF 结合。

Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiation.

机构信息

Department of Cancer Biology and Genetics, The Ohio State University, Columbus, OH, 43210, USA.

Laboratory of Cell and Developmental Signaling, National Cancer Institute-Frederick, Frederick, MD, 21702, USA.

出版信息

Nat Commun. 2022 Jun 7;13(1):3153. doi: 10.1038/s41467-022-30881-9.


DOI:10.1038/s41467-022-30881-9
PMID:35672316
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9174180/
Abstract

A distinct profile of NRAS mutants is observed in each tumor type. It is unclear whether these profiles are determined by mutagenic events or functional differences between NRAS oncoproteins. Here, we establish functional hallmarks of NRAS mutants enriched in human melanoma. We generate eight conditional, knock-in mouse models and show that rare melanoma mutants (NRAS G12D, G13D, G13R, Q61H, and Q61P) are poor drivers of spontaneous melanoma formation, whereas common melanoma mutants (NRAS Q61R, Q61K, or Q61L) induce rapid tumor onset with high penetrance. Molecular dynamics simulations, combined with cell-based protein-protein interaction studies, reveal that melanomagenic NRAS mutants form intramolecular contacts that enhance BRAF binding affinity, BRAF-CRAF heterodimer formation, and MAPK > ERK signaling. Along with the allelic series of conditional mouse models we describe, these results establish a mechanistic basis for the enrichment of specific NRAS mutants in human melanoma.

摘要

在每种肿瘤类型中都观察到 NRAS 突变体的独特特征。目前尚不清楚这些特征是由诱变事件还是 NRAS 癌蛋白之间的功能差异决定的。在这里,我们确定了在人类黑色素瘤中富集的 NRAS 突变体的功能特征。我们生成了八个条件性、敲入的小鼠模型,并表明罕见的黑色素瘤突变体(NRAS G12D、G13D、G13R、Q61H 和 Q61P)是自发黑色素瘤形成的不良驱动因素,而常见的黑色素瘤突变体(NRAS Q61R、Q61K 或 Q61L)则以高穿透率诱导快速肿瘤发生。分子动力学模拟,结合基于细胞的蛋白质-蛋白质相互作用研究,揭示了致黑色素瘤 NRAS 突变体形成增强 BRAF 结合亲和力、BRAF-CRAF 异二聚体形成和 MAPK>ERK 信号的分子内接触。结合我们描述的等位基因系列条件性小鼠模型,这些结果为 NRAS 突变体在人类黑色素瘤中的富集建立了一种机制基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce97/9174180/01bf00ad62b7/41467_2022_30881_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce97/9174180/e5f2b01c561b/41467_2022_30881_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce97/9174180/c505fdf016a8/41467_2022_30881_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce97/9174180/fcef2b334e2b/41467_2022_30881_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce97/9174180/75e6f92287e0/41467_2022_30881_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce97/9174180/53fc67dfa19d/41467_2022_30881_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce97/9174180/ef97bb59acd1/41467_2022_30881_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce97/9174180/b4277039c3bb/41467_2022_30881_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce97/9174180/01bf00ad62b7/41467_2022_30881_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce97/9174180/e5f2b01c561b/41467_2022_30881_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce97/9174180/c505fdf016a8/41467_2022_30881_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce97/9174180/fcef2b334e2b/41467_2022_30881_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce97/9174180/75e6f92287e0/41467_2022_30881_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce97/9174180/53fc67dfa19d/41467_2022_30881_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce97/9174180/ef97bb59acd1/41467_2022_30881_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce97/9174180/b4277039c3bb/41467_2022_30881_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce97/9174180/01bf00ad62b7/41467_2022_30881_Fig8_HTML.jpg

相似文献

[1]
Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiation.

Nat Commun. 2022-6-7

[2]
BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.

Histopathology. 2016-10

[3]
NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.

Diagn Pathol. 2015-7-25

[4]
Vemurafenib Drives Epithelial-to-Mesenchymal Transition Gene Expression in BRAF Inhibitor‒Resistant BRAF/NRAS Melanoma Enhancing Tumor Growth and Metastasis in a Bioluminescent Murine Model.

J Invest Dermatol. 2022-5

[5]
Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients.

J Dermatol Sci. 2015-10

[6]
[Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].

Magy Onkol. 2013-6

[7]
The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.

Br J Dermatol. 2013-11

[8]
MEK Inhibition Reverses Aberrant Signaling in Melanoma Cells through Reorganization of NRas and BRAF in Self Nanoclusters.

Cancer Res. 2021-3-1

[9]
RAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma.

Nat Commun. 2017-5-12

[10]
Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells.

J Biol Chem. 2014-10-3

引用本文的文献

[1]
Tumor-Associated NK Cells Regulate Distinct CD8+ T-cell Differentiation Program in Cancer and Contribute to Resistance against Immune Checkpoint Blockers.

Cancer Discov. 2025-6-18

[2]
Targeting the BCKDK/BCLAF1/MYC/HK2 axis to alter aerobic glycolysis and overcome Trametinib resistance in lung cancer.

Cell Death Differ. 2025-5-29

[3]
Papillary Thyroid Carcinoma With 5 Unique Point Mutations and Typical Behavior.

JCEM Case Rep. 2025-4-11

[4]
Dynamic conformational equilibria in the active states of KRAS and NRAS.

RSC Chem Biol. 2024-11-25

[5]
Pharmacological targeting of casein kinase 1δ suppresses oncogenic NRAS-driven melanoma.

Nat Commun. 2024-11-21

[6]
Current Insights into the Role of UV Radiation-Induced Oxidative Stress in Melanoma Pathogenesis.

Int J Mol Sci. 2024-10-30

[7]
Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapy.

ESMO Open. 2024-11

[8]
Inhibition and degradation of NRAS with a pan-NRAS monobody.

Oncogene. 2024-11

[9]
Mediating kinase activity in Ras-mutant cancer: potential for an individualised approach?

Front Pharmacol. 2024-9-20

[10]
Computational Modeling of Drug Response Identifies Mutant-Specific Constraints for Dosing panRAF and MEK Inhibitors in Melanoma.

Cancers (Basel). 2024-8-22

本文引用的文献

[1]
Structural insights into the BRAF monomer-to-dimer transition mediated by RAS binding.

Nat Commun. 2022-1-25

[2]
KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activation.

Nat Commun. 2021-2-19

[3]
A versatile toolbox for semi-automatic cell-by-cell object-based colocalization analysis.

Sci Rep. 2020-11-4

[4]
Drugging all RAS isoforms with one pocket.

Future Med Chem. 2020-11

[5]
KRAS Preferentially Signals through MAPK in a RAF Dimer-Dependent Manner in Non-Small Cell Lung Cancer.

Cancer Res. 2020-9-1

[6]
Ensembl 2020.

Nucleic Acids Res. 2020-1-8

[7]
Atypical KRAS Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer.

Cancer Discov. 2020-1

[8]
Distinct Binding Preferences between Ras and Raf Family Members and the Impact on Oncogenic Ras Signaling.

Mol Cell. 2019-10-9

[9]
Rapid Generation of Primary Murine Melanocyte and Fibroblast Cultures.

J Vis Exp. 2019-6-26

[10]
Strelka2: fast and accurate calling of germline and somatic variants.

Nat Methods. 2018-7-16

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索